Heart Failure Clinical Trial

Neuromodulation of Inflammation and Vascular Function in Systolic Heart Failure

Summary

Heart failure (HF) is the leading cause of death in US. It is associated with abnormal vascular function termed endothelial dysfunction. It is also associated with increased stress on the blood vessels and high levels of inflammation. Vagus nerve stimulation can help improve inflammation, vascular function and vascular stress. The investigator has recently completed a study showing that 1 hour of noninvasive vagus stimulation can improve vascular health. However, it is unknown if 4 weeks of stimulation will be beneficial in systolic heart failure.

The purpose of this study is to determine if transcutaneous vagal stimulation (TVS) will lead to improvement in the function of the inner lining of participants' arteries, memory, and in the levels of certain chemical markers of arterial function in the blood.

Participants will be randomized to receive either TVS or a sham stimulation and undergo 4 weeks of stimulation. Vascular function will be assessed by several non-invasive measurements, including Flow Mediate Dilation (FMD), Pulse Wave Analysis (PWA), EndoPAT, and Laser Speckle Contrast Imaging (LSCI). Participants' memory will also be measured through electronic assessments and blood will be collected and analyzed for arterial function chemical markers.

View Full Description

Full Description

Visit 1: Following tests(to assess vascular function) will be done: 1. FMD 2) LSCI 3) EndoPAT and 4) Pulse wave analysis (PWA). Patients will rest for 10 minutes between each test. They will be trained to use PARASYMTM unit for TVS. Blood collected, serum/plasma will be stored at -80F. Whole blood will be collected in PAXgene tubes. Patients will be instructed to apply TVS to either ear lobule (SHAM) or Tragus(experimental arm). Baseline characteristics will be collected including data on ventricular function(LVEF and left ventricular volumes).

Visit 2 (4 weeks): Follow up tests(FMD,LSCI,EndoPAT,PWA) and repeat blood collection.

Inflammatory cytokines and vascular function assays will be performed.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

1. Patients (18 years or older) with Heart failure with reduced ejection fraction (HFrEF), which is a history of symptomatic heart failure with left ventricular ejection fraction (LVEF) of < 40%.

Exclusion Criteria:

Patients in overt congestive heart failure / recent acute myocardial infarction (< 3 months) or Unstable angina
Active malignancy
Pre-menopausal women and post-menopausal women on hormone supplements.
Unilateral or bilateral vagotomy
Patients with bilateral upper extremity amputation
Pregnant patients
End-stage renal disease
End-stage liver disease
History of recurrent vasovagal syncope, Sick sinus syndrome, 2nd- or 3rd-degree atrioventricular (AV) block.
Patients with clinically documented upper extremity arterial disease
Patients with a body mass index (BMI) >35
Significant hypotension (blood pressure <90mmHg) secondary to autonomic dysfunction

Study is for people with:

Heart Failure

Estimated Enrollment:

7

Study ID:

NCT03945058

Recruitment Status:

Terminated

Sponsor:

University of Oklahoma

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

University of Oklahoma Health Sciences Center
Oklahoma City Oklahoma, 73104, United States

How clear is this clinincal trial information?

Study is for people with:

Heart Failure

Estimated Enrollment:

7

Study ID:

NCT03945058

Recruitment Status:

Terminated

Sponsor:


University of Oklahoma

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider